These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31984569)

  • 21. Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
    Ishidoya M; Makiguchi T; Tanaka H; Miura T; Nunomura Y; Miura D; Morimoto T; Hasegawa Y; Taima K; Tasaka S
    Lung Cancer; 2024 Jun; 192():107790. PubMed ID: 38696920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.
    Yokoyama R; Sato Y; Nakamura F; Kagemoto K; Mitsui Y; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
    Clin J Gastroenterol; 2023 Dec; 16(6):842-847. PubMed ID: 37632658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort.
    Ksienski D; Truong PT; Wai ES; Croteau NS; Chan A; Patterson T; Clarkson M; Hackett S; Irons S; Lesperance M
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e561-e569. PubMed ID: 34226113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.
    Saijo K; Imai H; Ouchi K; Okada Y; Sato Y; Komine K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
    Tohoku J Exp Med; 2019 May; 248(1):37-43. PubMed ID: 31105123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on the safety of nivolumab for the treatment of advanced melanoma.
    Czarnecka AM; Rutkowski P
    Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
    [No Abstract]   [Full Text] [Related]  

  • 30. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study.
    Okada N; Kawazoe H; Takechi K; Matsudate Y; Utsunomiya R; Zamami Y; Goda M; Imanishi M; Chuma M; Hidaka N; Sayama K; Kubo Y; Tanaka A; Ishizawa K
    Clin Ther; 2019 Jan; 41(1):59-67. PubMed ID: 30528047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
    Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
    Bai X; Hu J; Betof Warner A; Quach HT; Cann CG; Zhang MZ; Si L; Tang B; Cui C; Yang X; Wei X; Pallan L; Harvey C; Manos MP; Ouyang O; Kim MS; Kasumova G; Cohen JV; Lawrence DP; Freedman C; Fadden RM; Rubin KM; Sharova T; Frederick DT; Flaherty KT; Rahma OE; Long GV; Menzies AM; Guo J; Shoushtari AN; Johnson DB; Sullivan RJ; Boland GM
    Clin Cancer Res; 2021 Nov; 27(21):5993-6000. PubMed ID: 34376536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab.
    Ksienski D; Wai ES; Croteau NS; Freeman AT; Chan A; Fiorino L; Poonja Z; Fenton D; Patterson T; Irons S; Lesperance M
    J Geriatr Oncol; 2020 Jun; 11(5):807-813. PubMed ID: 31937494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
    Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab.
    Suematsu H; Kano K; Yamada T; Hashimoto I; Watanabe H; Takahashi K; Watanabe M; Hayashi K; Kaneta Y; Furuta M; Inokuchi Y; Machida N; Aoyama T; Tamagawa H; Yukawa N; Rino Y; Masuda M; Ogata T; Oshima T
    Anticancer Res; 2022 Mar; 42(3):1535-1540. PubMed ID: 35220249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
    Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A
    PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
    Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
    Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
    Cybulska-Stopa B; Pacholczak-Madej R; Kamińska-Winciorek G; Ziętek M; Czarnecka AM; Piejko K; Galus Ł; Ziółkowska B; Kieszko S; Kempa-Kamińska N; Calik J; Rolski J; Sałek-Zań A; Gajewska-Wicher K; Drosik-Kwaśniewska A; Rogala P; Kubiatowski T; Suwiński R; Mackiewicz J; Rutkowski P
    Immunotherapy; 2021 Mar; 13(4):297-307. PubMed ID: 33353420
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.